UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 546

Sortiert nach

Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species

European journal of clinical microbiology & infectious diseases, 2024-03, Vol.43 (3), p.559-566

2024

Volltextzugriff (PDF)

ATIVIDADE IN VITRO DE NOVOS ANTIMICROBIANOS/COMBINAÇÕES CONTRA ISOLADOS CLÍNICOS DE KLEBSIELLA E PSEUDOMONAS RESISTENTES AOS CARBAPENÊMICOS

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.102817

2023

Volltextzugriff (PDF)

Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect

Clinical microbiology and infection, 2021-08, Vol.27 (8), p.1172.e7-1172.e10

2021

Volltextzugriff (PDF)

New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae

Antimicrobial agents and chemotherapy, 2022-02, Vol.66 (2), p.e0201121-e0201121

2022

Volltextzugriff (PDF)

Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus

Annals of clinical microbiology and antimicrobials, 2024-08, Vol.23 (1), p.78-12

2024

Volltextzugriff (PDF)

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies

Diagnostic microbiology and infectious disease, 2024-09, Vol.110 (1), p.116372, Article 116372

2024

Volltextzugriff (PDF)

Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales

Clinical microbiology and infection, 2022-11, Vol.28 (11), p.1503.e1-1503.e3

2022

Volltextzugriff (PDF)

Electrochemical detection of cefiderocol for therapeutic drug monitoring

Electrochemistry communications, 2021-12, Vol.133, p.107147, Article 107147

2021

Volltextzugriff (PDF)

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

Journal of global antimicrobial resistance., 2020-09, Vol.22, p.738-741

2020

Volltextzugriff (PDF)

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Clinical infectious diseases, 2022-08, Vol.75 (2), p.187-212

2022

Volltextzugriff (PDF)

Pan-drug resistant Providencia rettgeri contributing to a fatal case of COVID-19

Journal of medical microbiology, 2021-08, Vol.70 (8)

2021

Volltextzugriff (PDF)

Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective

Expert opinion on pharmacotherapy, 2021-02, Vol.22 (2), p.167-177

2021

Volltextzugriff (PDF)

The solution to drug resistance of Gram-negative bacteria – Cefiderocol

Journal of education, health and sport, 2023-05, Vol.33 (1), p.17-21

2023

Volltextzugriff (PDF)

The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy

Antimicrobial agents and chemotherapy, 2024-01, Vol.68 (1), p.e0100923

2024

Volltextzugriff (PDF)

Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis

International journal of antimicrobial agents, 2024-02, Vol.63 (2), p.107047, Article 107047

2024

Volltextzugriff (PDF)

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Clinical infectious diseases, 2021-06, Vol.72 (11), p.2021-2024

2021

Volltextzugriff (PDF)

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

The Lancet infectious diseases, 2021-02, Vol.21 (2), p.226-240

2021

Volltextzugriff (PDF)

Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?

Journal of clinical microbiology, 2020-12, Vol.59 (1)

2020

Volltextzugriff (PDF)

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

Clinical infectious diseases, 2019-11, Vol.69 (Supplement_7), p.S538-S543

2019

Volltextzugriff (PDF)

Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients

Clinical microbiology and infection, 2023-04, Vol.29 (4), p.538.e7-538.e13

2023

Volltextzugriff (PDF)

Genomic Modification of TonB and Emergence of Small-Colony Phenotype in VIM- and NDM-Producing Escherichia coli following Cefiderocol Exposure In Vitro

Antimicrobial agents and chemotherapy, 2023-05, Vol.67 (5), p.e0011823-e0011823

2023

Volltextzugriff (PDF)

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Antimicrobial agents and chemotherapy, 2019-01, Vol.63 (1)

2019

Volltextzugriff (PDF)

Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa

International journal of antimicrobial agents, 2023-09, Vol.62 (3), p.106917-106917, Article 106917

2023

Volltextzugriff (PDF)

Efficacy of cefiderocol, a novel siderophore cephalosporin, against multi-drug resistant Acinetobacter baumannii clinical isolates in Japan

Japanese Journal of Infectious Diseases, 2024/01/31, pp.JJID.2023.364

2024

Volltextzugriff (PDF)

Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis

The Journal of infection, 2024-03, Vol.88 (3), p.106113, Article 106113

2024

Volltextzugriff (PDF)

1 – 25 von 546

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(524)
Mit Volltextzugriff
(486)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Cefiderocol
(535)
Science & Technology
(487)
Life Sciences & Biomedicine
(476)
Humans
(295)
Infectious Diseases
(276)
Microbiology
(275)
Pharmacology & Pharmacy
(262)
Anti-Bacterial Agents - Pharmacology
(253)
Microbial Sensitivity Tests
(238)
Anti-Bacterial Agents - Therapeutic Use
(171)
Cephalosporins - Pharmacology
(170)
Gram-Negative Bacteria
(152)
Antibiotics
(137)
Pseudomonas Aeruginosa
(118)
Cephalosporins
(111)
Acinetobacter Baumannii
(91)
Drug Resistance, Multiple, Bacterial
(90)
Cephalosporins - Therapeutic Use
(88)
Carbapenems - Pharmacology
(74)
Beta-Lactamases - Genetics
(72)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(17)

Menü

Weitere Dienste

Einstellungen

Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species

ATIVIDADE IN VITRO DE NOVOS ANTIMICROBIANOS/COMBINAÇÕES CONTRA ISOLADOS CLÍNICOS DE KLEBSIELLA E PSEUDOMONAS RESISTENTES AOS CARBAPENÊMICOS

Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect

New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae

Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies

Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales

Electrochemical detection of cefiderocol for therapeutic drug monitoring

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pan-drug resistant Providencia rettgeri contributing to a fatal case of COVID-19

Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective

The solution to drug resistance of Gram-negative bacteria – Cefiderocol

The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy

Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients

Genomic Modification of TonB and Emergence of Small-Colony Phenotype in VIM- and NDM-Producing Escherichia coli following Cefiderocol Exposure In Vitro

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa

Efficacy of cefiderocol, a novel siderophore cephalosporin, against multi-drug resistant Acinetobacter baumannii clinical isolates in Japan

Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis

Suchergebnisse filtern